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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate to the effects of transcutaneous screening for hyperbilirubinemia to prevent the readmission of neonates for phototherapy.
B A C K G R O U N D
Description of the condition
Hyperbilirubinemia is a term used to describe elevated levels of
bilirubin in the blood. In newborns, hyperbilirubinemia becomes
clinically apparent as jaundice, a yellow coloration of the skin and
the sclera, at serum bilirubin levels > 5 mg/dL (Porter 2002). Hy-
perbilirubinemia is very common in both term and preterm new-
born infants (occurring in around 60% of newborns) and results
from a predisposition to produce bilirubin and the newborn’s lim-
ited ability to excrete it (Lauer 2011). Jaundice or hyperbiliru-
binemia is the most common cause of hospital readmission in the
neonatal period (Soskolne 1996; Maisels 1998; Escobar 2005).
Most cases of newborn jaundice are mild and self limited. How-
ever, in rare cases, infants can have very high levels of bilirubin that
can lead to bilirubin encephalopathy and kernicterus (Newman
2006). The threshold concentration of bilirubin and/or the dura-
tion of hyperbilirubinemia responsible for causing kernicterus in-
jury in newborn infants is not known (Dennery 2004). Low con-
centrations of bilirubin may have some antioxidant benefits, sug-
gesting that bilirubin should not be completely eliminated. Stud-
ies from developed countries estimate the incidence of kernicterus
to range from about 0.4 to 2 per 100,000 (Sgro 2006; Manning
2007; Burke 2009). However, studies from developing countries
suggest that the incidence may be much higher (Nair 2003; Owa
2009).
The acute phase signs of kernicterus are poor feeding, lethargy,
high-pitched cry, hypertonia or hypotonia, opisthotonos and
seizures. The chronic manifestations include athetoid cerebral
palsy, motor delay, gaze palsy, dental dysplasia, mental retardation
and sensorineural hearing loss (AAP 2004). Current treatments
for hyperbilirubinemia include phototherapy and exchange trans-
fusion (usually reserved for severe cases of hyperbilirubinemia)
(NICE 2010).
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Description of the intervention
Transcutaneous bilirubin (TcB) measurement devices are used for
the rapid and noninvasive measurement of bilirubin levels in the
skin.Transcutaneous bilirubinometryworks by directing light into
the skin of the neonate and measuring the intensity of the spe-
cific wavelength of light returned. The measurement is usually
taken by gently pressing the meter against the sternum. Find-
ings from many studies suggest that the accuracy and precision
of TcB measurements are correlate with standard laboratory to-
tal serum bilirubin (TsB) (Rubaltelli 2001; Engle 2002; Maisels
2004; Slusher 2004; Jangaard 2006). Other studies suggest that
TcB measurements do not correlate with TsB measurements in
preterm newborn (Knupfer 2001; Karoly 2004). TcB screening
involves the measurement of bilirubin in every newborn in whom
clinical jaundice is not present or observed, prior to discharge.
How the intervention might work
The practice of early discharge (< 72 hours of age) of healthy term
newborns is growing worldwide. Because peak serum bilirubin
levels usually occur on postnatal days three to five, an effective
means of screening for the onset of hyperbilirubinemia could en-
hance the safety of the early discharge of newborns.
The clinical evaluation of hyperbilirubinemia involves the visual
assessment of jaundice. However, this method can be affected by
the newborn’s skin color and does not provide a quantification of
the TsB level. Current, more-objective methods of assessing hy-
perbilirubinemia include the use of TsB measurements from blood
sampling and noninvasive methods, such as TcB measurement
with a handheld bilirubinometer. To aid in identifying newborns
with a significant risk of hyperbilirubinemia and its consequences,
TcB and other screening strategies for hyperbilirubinemia prior to
the discharge of newborns have been advocated (Bhutani 1999;
Alpay 2000; Newman 2000; Stevenson 2001). Transcutaneous
screening for hyperbilirubinemia is used to identify newborns with
bilirubin levels greater than the 75th percentile for age in hours
and to track those with rapid rates of bilirubin rise (> 0.2 mg per
100 mL per hour). Bhutani 1999 proposed an on-the-hour-spe-
cific bilirubin nomogram as an approach to predischarge screen-
ing for hyperbilirubinemia. However, Fay 2009 have highlighted
multiple methodologic flaws in the methods used to create the
hour-specific total bilirubin nomogram.
Transcutaneous screening for hyperbilirubinemia, the characteri-
zation of bilirubin levels by risk, with selective follow up of at-risk
infants and timely intervention in infants at risk of hyperbiliru-
binemia, could lead to a reduction in the number of newborns
with severe hyperbilirubinemia and a reduction in the number of
newborns readmitted to the hospital for phototherapy or exchange
transfusion. If hyperbilirubinemia is identified early, effective in-
terventions such as phototherapy can be initiated to reduce the
risk bilirubin encephalopathy. However, TcB screening could also
lead to unnecessary readmissions, prolonged hospitalization, ex-
cess laboratory tests and increased costs.
Why it is important to do this review
The American Academy of Pediatrics (AAP) and the Canadian
Pediatric Society both recommend the use of either predischarge
serumbilirubin orTcBmeasurements as appropriate screening op-
tions for identifying infants at risk of neonatal hyperbilirubinemia
(AAP 2004; CPS 2007). In contrast, however, according to the
US Preventive Services Task Force, “there is insufficient evidence
to make a recommendation on screening infants for hyperbiliru-
binemia to prevent chronic bilirubin encephalopathy” (USPSTF
2009). There is conflicting evidence for, and recommendations
on, the usefulness of predischarge bilirubin screening in newborns.
Without proof of efficacy, universal screening of newborns for hy-
perbilirubinemia can result in the waste of healthcare resources
and the unnecessary testing of many newborns.
We aim to evaluate all the relevant available evidence to assess
the effects of transcutaneous screening for hyperbilirubinemia in
newborn infants before discharge from hospital.
O B J E C T I V E S
To evaluate to the effects of transcutaneous screening for hyper-
bilirubinemia to prevent the readmission of neonates for pho-
totherapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials, quasirandomized
controlled trials, cluster randomized trials and other prospective
study designs (e.g. cohort studies).
Types of participants
• Well newborns, of gestational age 35 weeks or more and
weighing 1800 g or more, being discharged from the newborn
nursery (in the first week of life)
We will not include infants admitted to, or being discharged from,
the neonatal intensive care unit.
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Types of interventions
1. TcB screening (alone or combined with any other method, e.g.
visual assessment) compared to no screening or visual inspection
for hyperbilirubinemia before discharge from hospital
2. TcB screening versus serum bilirubin screening before discharge
from hospital
3. Closer follow up or home nursing visits based on TcB screening
results versus postdischarge follow up or treatment decisions based
on visual inspection
Types of outcome measures
Primary outcomes
• Readmission for phototherapy or home phototherapy for
hyperbilirubinemia
• Exchange transfusion
Secondary outcomes
• Phototherapy before hospital discharge
• Peak bilirubin levels
• Acute bilirubin encephalopathy
• Chronic bilirubin encephalopathy
• Hearing loss
• Length of stay (days)
• Cost of care
Search methods for identification of studies
We will use the standard search strategy of the Cochrane Neona-
tal Review Group to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press and
in progress).
Electronic searches
We will search the following electronic databases: the Cochrane
Central Register of Controlled Trials (CENTRAL, The Cochrane
Library - current),MEDLINE (1950 to current), EMBASE (1980
to current) and CINAHL (1982 to current).We will searchMED-
LINE, EMBASE and CINAHL for relevant articles using the
search terms: [Infant OR Newborn (explode) [MeSH heading]
AND transcutaneous (explode) [MeSH heading] OR screening
AND [hyperbilirubinaemia OR hyperbilirubinemia OR jaundice
(explode) [MeSH heading]]. We will search clinical trial registries
for any ongoing trials (www.clinicaltrials.gov; www.controlled-
trials.com/ and www.who.int/ictrp).
Searching other resources
We will attempt to contact experts and organizations or manufac-
turers of bilirubinometers for information on any relevant study.
We will scan through the reference lists of all relevant studies. We
will search any previous reviews, including cross-references and
abstracts, and conference and symposia proceedings of the Perina-
tal Society of Australia and New Zealand and the Paediatric Aca-
demic Societies (American Pediatric Society, Society for Pediatric
Research and European Society for Paediatric Research).
Data collection and analysis
We will use the standard methods of the Cochrane Neonatal Re-
view Group.
Selection of studies
The first two review authors will independently scan through the
titles and abstracts of the search output to identify potentially el-
igible studies. Discrepancies will be resolved through discussion
or, if required, we will consult the third author. We will obtain
full text articles of all selected abstracts to formally assess eligi-
bility using the prespecied eligibility criteria. We will summarize
the reasons for exclusion of any potentially eligible study in the
‘Characteristics of excluded studies’ table.
Data extraction and management
We will design a data extraction form for the extraction of data.
Two review authors will independently extract data from all in-
cluded studies using the data extraction form. We will resolve dis-
crepancies through discussion or, if required, we will consult the
third review author. We will enter data into the latest version of
Review Manager (RevMan 2011) and check them for accuracy.
We will contact authors of the studies identified via email or tele-
phone to provide more information, if necessary.
Study information that will be extracted will include:
• study details: citation, start and end dates, location and
study design;
• participant details: study population eligibility (inclusion
and exclusion) criteria, gestational age, sex, sample size and
attrition rate;
• details about the interventions: type of transcutaneous
bilirubin meter used and any other method used for screening
for hyperbilirubinemia
• outcome details: readmission rates for phototherapy,
exchange transfusion, acute bilirubin encephalopathy, chronic
bilirubin encephalopathy and adverse effects.
3Transcutaneous screening for hyperbilirubinemia in neonates (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For each dichotomous outcome, we will extract information on
the number of participants experiencing the event and the num-
ber of participants randomized to each treatment group. For each
continuous outcome wewill extract themeans or geometric means
and standard deviations (or information to estimate the standard
deviations) for each treatment group, together with the numbers
of participants in each group. Medians and ranges will also be ex-
tracted if these are reported in place of means and standard devi-
ations.
Assessment of risk of bias in included studies
The first two review authors will independently assess the risk
of bias in each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreement by discussion or by consulting
the third review author.
(1) Sequence generation (checking for possible selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups. We will
assess the method as:
• adequate (any truly random process, e.g. random number
table; computer random number generator);
• inadequate (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);
• unclear (if we do not find enough information to make a
judgment).
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to
conceal the allocation sequence in sufficient detail and determine
whether intervention allocation could have been foreseen in ad-
vance of or during recruitment, or changed after assignment. We
will assess the methods as:
• adequate (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or
nonopaque envelopes; alternation; date of birth);
• unclear (if we do not find enough information to make a
judgment).
(3) Blinding (checking for possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will judge studies
to be at low risk of bias if they were blinded, or if we judge that the
lack of blinding could not have affected the results. We will assess
blinding separately for different outcomes or classes of outcomes.
We will assess the methods as:
• adequate, inadequate or unclear for participants;
• adequate, inadequate or unclear for personnel;
• adequate, inadequate or unclear for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data, including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported, the numbers included in the analysis
at each stage (compared with the total numbers of randomized
participants), reasons for attrition or exclusion where reported,
and whether missing data were balanced across groups or were
related to outcomes. Where sufficient information is reported, or
can be supplied by the trial authors, we will reinclude missing data
in the analyses that we undertake. We will assess methods as:
• adequate (where fewer than 20% of data are missing);
• inadequate (where more than 20% of the data are missing);
• unclear (if we do not find enough information to make a
judgment).
(5) Selective reporting bias
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• adequate (where it is clear that all of the study’s prespecied
outcomes and all expected outcomes of interest to the review
have been reported);
• inadequate (where not all the study’s prespecied outcomes
have been reported; one or more reported primary outcomes were
not prespecied; outcomes of interest are reported incompletely
and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear (if we do not find enough information to make a
judgment).
(6) Other sources of bias
We will describe for each included study any important concerns
we have about other possible sources of bias.Wewill assess whether
each study was free of other problems that could put it at risk of
bias as: yes, no or unclear.
Measures of treatment effect
We will present results for dichotomous outcomes as summary
risk ratios (RRs) with 95% confidence intervals (CIs) and absolute
risk differences with 95% CIs. Continuous outcomes will be pre-
sented using the mean difference (MD), if outcomes are measured
using the same scale in trials, or using the standardized mean dif-
ference when the outcome is measured using different scales. The
summary effect measures will be presented with 95% CIs. If the
RR is statistically significant, the number needed to treat to for an
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additional beneficial outcome (NNTB) or an additional harmful
outcome (NNTH) will be calculated.
Unit of analysis issues
We will note the unit of analysis at the level of randomization
(individual or group) and analyze the data accordingly. We will in-
clude cluster randomized trials in the analyses along with individ-
ually randomized trials. For cluster randomized trials, we will ad-
just the sample sizes using the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions, Section 16.3.4 or
16.3.6 (Higgins 2011) using an estimate of the intracluster corre-
lation coefficient (ICC) derived from the trial (if possible) or from
another source.
Dealing with missing data
We will attempt to contact authors if there are missing or unclear
data. We will also note levels of attrition in each of the included
studies. For all outcomes we will carry out an intention-to-treat
analysis. For outcomes in which the results have been pooled in
meta-analysis, we will explore the impact of including studies with
significant loss to follow up in the overall assessment of treatment
effect by using sensitivity analyses.
Assessment of heterogeneity
We will assess statistical heterogeneity by visually inspecting the
forest plots to detect overlapping CIs, applying the Chi2 test (P
value < 0.10 considered statistically significant) and also using
the I2 statistic, where an I2 of less than 25% will be considered
as unimportant, 25% to 49% will be considered to suggest low
heterogeneity, 50% to 74%will be considered to suggest moderate
heterogeneity, and 75% or greater will be considered to indicate
high heterogeneity.
Assessment of reporting biases
If we have 10 or more studies, we will explore the likelihood of
reporting bias or publication bias for each outcome using funnel
plots.
Data synthesis
We will analyze the data using ReviewManager 5.2.7. Where pos-
sible, we will adjust for the effect of clustering in cluster random-
ized trials and combine the results with results from individually
randomized studies in meta-analysis. We will use a random-effect
model for any meta-analyses.
Quality of evidence
The quality of evidence across each outcome measure will be as-
sessed using the GRADE approach. GRADE defines the quality
of evidence as the confidence we have in the estimate of effect for
an outcome (Atkins 2004). The quality rating across studies has
four levels: high, moderate, low or very low. Randomized trials are
categorized as high quality, but can be downgraded. Some of the
factors that would impact on the quality of evidence are the risk of
bias in included studies, the presence of unexplained heterogene-
ity or inconsistency, the imprecision of results, indirectness of the
evidence and publication bias (Balshem 2011).
Subgroup analysis and investigation of heterogeneity
We plan to carry out subgroup analyses based on gestation age
(preterm versus term newborns); the presence of jaundice (versus
no jaundice) in newborns; birth weight (<2500g versus > 2500g);
and the presence of any comorbid conditions (e.g. hemolytic dis-
ease or other conditions known to exacerbate jaundice); mode of
delivery (spontaneous vertex delivery or delivery by caesarean sec-
tion).
Sensitivity analysis
Depending on the number of included studies, we plan to con-
duct sensitivity analyses on the robustness of the methods used
regarding allocation concealment and losses to follow up in the
analysis, and we will report the impact of the sensitivity analyses
on the quantitative results from the meta-analysis.
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